JPMorgan analyst Chris Schott upgraded Teva (TEVA) to Overweight from Neutral with a price target of $23, up from $21. The firm says the company’s recently announced cost-cutting program provides “much-needed clarity” on the drivers of its margin expansion in 2026 and 2027. Teva’s margin trajectory had been a primary concern on the story as the company works through the step down in generic Revlimid while also needing to invest behind its pipeline, the analyst tells investors in a research note. JPMorgan now sees Teva’s growth improving significantly as it looks out to 2027 and beyond driven by the company’s branded business including Austedo.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva price target raised to $22 from $20 at BofA
- Teva Pharmaceuticals: Positioned for Growth with Strategic Cost-Saving Initiatives and New Product Cycle
- Teva Reports Strong Q1 2025 Growth with Innovative Medicines
- Teva Pharmaceuticals’ Earnings Call: Growth and Strategic Focus
- Teva reports Q1 EPS 52c, consensus 46c
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue